NA
ABBV icon

Nordwand Advisors’s AbbVie ABBV Stock Holding History

Nordwand Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Buy
52,237
+830
+2% +$179K 2.02% 13
2026
Q1 		$11.2M Buy
51,407
+3,150
+7% +$699K 1.96% 11
2025
Q4 		$11M Buy
48,257
+5
+0% +$1.14K 1.93% 13
2025
Q3 		$11.2M Buy
48,252
+2,086
+5% +$425K 1.77% 13
2025
Q2 		$8.57M Buy
46,166
+45,684
+9,478% +$8.49M 1.34% 15
2025
Q1 		$101K Hold
482
– – 0.04% 34
2024
Q4 		$85.7K Hold
482
– – 0.04% 40
2024
Q3 		$95.2K Sell
482
-1,400
-74% -$261K 0.03% 37
2024
Q2 		$323K Sell
1,882
-5,013
-73% -$830K 0.14% 20
2024
Q1 		$1.26M Sell
6,895
-12,295
-64% -$2.12M 0.49% 20
2023
Q4 		$2.97M Buy
19,190
+68
+0.4% +$9.91K 0.78% 18
2023
Q3 		$2.85M Sell
19,122
-3,283
-15% -$482K 0.56% 16
2023
Q2 		$3.02M Sell
22,405
-148
-0.7% -$21.7K 0.52% 19
2023
Q1 		$3.59M Sell
22,553
-34,021
-60% -$5.2M 0.59% 16
2022
Q4 		$9.14M Buy
+56,574
New +$8.67M 1.14% 9

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Nordwand Advisors's ABBV Position: Q2 2026 in Review

Nordwand Advisors increased its AbbVie (ABBV) stake by 1.6% in Q2 2026, buying an estimated $179K and bringing the position to 52,237 shares worth $13.1M. The position accounts for 2.02% of the portfolio, ranked #13.

Nordwand Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Nordwand Advisors held 52,237 shares of AbbVie worth $13.1M as of Q2 2026.
  • Nordwand Advisors bought 830 AbbVie shares in Q2 2026, an estimated $179K.
  • AbbVie made up 2.02% of Nordwand Advisors's portfolio in Q2 2026, its #13 holding.
  • Nordwand Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Nordwand Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.